The estimated Net Worth of Heather Ann Mc Sharry is at least $3.63 Milhão dollars as of 11 August 2023. Ms. Sharry owns over 1,344 units of Jazz Pharmaceuticals plc stock worth over $1,763,871 and over the last 12 years she sold JAZZ stock worth over $1,301,210. In addition, she makes $567,573 as Independent Director at Jazz Pharmaceuticals plc.
Heather has made over 11 trades of the Jazz Pharmaceuticals plc stock since 2015, according to the Form 4 filled with the SEC. Most recently she sold 1,344 units of JAZZ stock worth $185,687 on 11 August 2023.
The largest trade she's ever made was exercising 8,000 units of Jazz Pharmaceuticals plc stock on 5 August 2022 worth over $442,240. On average, Heather trades about 995 units every 172 days since 2013. As of 11 August 2023 she still owns at least 16,778 units of Jazz Pharmaceuticals plc stock.
You can see the complete history of Ms. Sharry stock trades at the bottom of the page.
Heather Ann McSharry serves as Independent Director of the Company. Heather Ann McSharry has served as a member of our board of directors since May 2013 and was appointed as chairperson of our nominating and corporate governance committee in August 2017. Ms. McSharry currently serves as a non-executive director on the boards of directors of several public and private companies, including CRH plc, an international building materials group, Greencore Group plc, an international manufacturer of convenience foods and Uniphar plc, a diversified healthcare services company. From 2006 to 2009, Ms. McSharry was Managing Director Ireland of Reckitt Benckiser, a multinational health, home and hygiene consumer products company. From 1989 to 2006, she held various positions at Boots Healthcare, a leading global consumer healthcare company, most recently as Managing Director of Boots Healthcare Ireland Limited. Ms. McSharry served on the board of directors of the Bank of Ireland from 2007 to 2011 and on the board of the Industrial Development Agency in Ireland from 2010 to 2014. Ms. McSharry holds a Bachelor of Commerce and a Master of Business Studies degree from University College Dublin.
As the Independent Director of Jazz Pharmaceuticals plc, the total compensation of Heather McSharry at Jazz Pharmaceuticals plc is $567,573. There are 11 executives at Jazz Pharmaceuticals plc getting paid more, with Bruce Cozadd having the highest compensation of $14,713,600.
Heather McSharry is 58, she's been the Independent Director of Jazz Pharmaceuticals plc since 2013. There are 8 older and 18 younger executives at Jazz Pharmaceuticals plc. The oldest executive at Jazz Pharmaceuticals plc is Catherine Sohn, 67, who is the Independent Director.
Heather's mailing address filed with the SEC is 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, L2, .
Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over $1,513,676,247 worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth $25,188,964 . The most active insiders traders include Michael W Michelson, Patrick G Enright, eJp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of $5,162,934. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth $152,703.
jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni
Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include: